We are disappointed by NICE’s draft decision not to recommend Cabotegravir long-acting (CAB-LA), an injectable PrEP option that could help increase PrEP uptake among women, Black African communities, and #marginalised communities.

 

“CAB-LA has the potential to significantly benefit other groups, including women, homeless people, the prison population, transgender and gender diverse individuals, and others currently underserved by existing prevention options. These communities are known to be more likely to acquire HIV and to face barriers to healthcare and oral PrEP. CAB-LA provides a discreet, long-acting alternative that could help address these unmet needs.”

 

Find out more in the HIV sector joint statement.